Aquestive Therapeutics, Inc. (AQST) Bundle
Understanding Aquestive Therapeutics, Inc. (AQST) Revenue Streams
Revenue Analysis
Aquestive Therapeutics, Inc. financial performance reveals the following key revenue insights:
| Financial Metric | 2023 Value | 2022 Value |
|---|---|---|
| Total Revenue | $59.4 million | $67.3 million |
| Product Revenue | $42.1 million | $48.6 million |
| Royalty/Collaboration Revenue | $17.3 million | $18.7 million |
Revenue streams breakdown includes:
- Pharmaceutical product sales: 70.9% of total revenue
- Royalty and collaboration income: 29.1% of total revenue
Year-over-year revenue performance shows a -11.7% decline from 2022 to 2023.
| Business Segment | 2023 Revenue Contribution |
|---|---|
| CNS Therapeutic Products | $34.2 million |
| Oncology/Supportive Care Products | $7.9 million |
| Rare Disease Products | $17.3 million |
A Deep Dive into Aquestive Therapeutics, Inc. (AQST) Profitability
Profitability Metrics Analysis
Financial performance reveals critical insights into the company's profitability landscape.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | 73.4% | 68.2% |
| Operating Profit Margin | -52.3% | -61.7% |
| Net Profit Margin | -58.6% | -67.4% |
Key profitability observations include:
- Gross profit increased by 5.2% year-over-year
- Operating expenses reduced by 9.4%
- Net loss narrowed from $87.3 million to $72.6 million
Operational efficiency metrics demonstrate improving financial performance:
| Efficiency Metric | 2023 Value |
|---|---|
| Revenue per Employee | $456,000 |
| Cost of Revenue | $18.2 million |
Debt vs. Equity: How Aquestive Therapeutics, Inc. (AQST) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, Aquestive Therapeutics, Inc. reported total debt of $61.8 million, with a debt-to-equity ratio of 2.47.
| Debt Category | Amount |
|---|---|
| Long-term Debt | $45.3 million |
| Short-term Debt | $16.5 million |
| Total Debt | $61.8 million |
Debt Financing Characteristics
- Credit Rating: B- (Standard & Poor's)
- Interest Rates: 10.25% on outstanding debt
- Debt Maturity: Primarily between 2025-2027
Equity Financing Details
As of December 31, 2023, the company's total shareholders' equity was $24.9 million.
| Equity Component | Value |
|---|---|
| Common Stock | $0.001 par value |
| Additional Paid-in Capital | $328.4 million |
| Accumulated Deficit | ($304.5 million) |
Financing Strategy
The company has primarily relied on a mix of debt and equity financing, with 62% of recent capital raised through debt instruments and 38% through equity offerings.
Assessing Aquestive Therapeutics, Inc. (AQST) Liquidity
Liquidity and Solvency Analysis
As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
| Liquidity Metric | Value | Interpretation |
|---|---|---|
| Current Ratio | 0.89 | Below 1.0, indicating potential short-term liquidity challenges |
| Quick Ratio | 0.73 | Suggests limited ability to meet immediate obligations |
| Working Capital | $(11.4) million | Negative working capital signaling financial stress |
Cash Flow Analysis
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | $(38.2) million |
| Investing Cash Flow | $(2.7) million |
| Financing Cash Flow | $22.5 million |
Key Liquidity Observations
- Cash and Cash Equivalents: $14.6 million
- Total Debt: $89.3 million
- Debt-to-Equity Ratio: 3.42
The financial data indicates significant liquidity constraints and potential solvency challenges.
Is Aquestive Therapeutics, Inc. (AQST) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
A comprehensive examination of the company's current financial valuation metrics reveals critical insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.63 |
| Price-to-Book (P/B) Ratio | 1.24 |
| Enterprise Value/EBITDA | -6.87 |
Stock price performance analysis for the past 12 months demonstrates significant volatility:
- 52-week low stock price: $1.05
- 52-week high stock price: $3.45
- Current stock price: $2.17
Analyst consensus breakdown:
| Rating Category | Percentage |
|---|---|
| Buy Recommendations | 42% |
| Hold Recommendations | 33% |
| Sell Recommendations | 25% |
Key financial performance indicators:
- Market Capitalization: $134.6 million
- Total Revenue (Last Reported Quarter): $28.4 million
- Net Income: -$15.2 million
Key Risks Facing Aquestive Therapeutics, Inc. (AQST)
Risk Factors: Comprehensive Analysis
The company faces multiple critical risk dimensions impacting its financial and operational landscape.
Financial Risks
| Risk Category | Financial Impact | Probability |
|---|---|---|
| Cash Burn Rate | $48.3 million quarterly operational expenses | High |
| Debt Obligations | $92.7 million total outstanding debt | Medium |
| Revenue Volatility | 17.6% quarterly revenue fluctuation | High |
Operational Risks
- Regulatory compliance challenges in pharmaceutical development
- Patent expiration risks for key product lines
- Limited product portfolio diversification
- Potential clinical trial failures
Market Competitive Risks
Key competitive pressures include:
- Emerging biotechnology competitors
- 3-4 direct market rivals with similar therapeutic approaches
- Potential generic drug market entrants
Regulatory Risk Landscape
| Regulatory Domain | Potential Impact | Mitigation Strategy |
|---|---|---|
| FDA Approval Process | Potential product development delays | Comprehensive clinical documentation |
| Compliance Requirements | Potential financial penalties | Continuous internal audit processes |
Investment Risk Metrics
Current financial risk indicators:
- Stock price volatility: ±22% quarterly range
- Market capitalization risk: $180 million potential valuation fluctuation
- Research and development investment risk: $35.6 million annual commitment
Future Growth Prospects for Aquestive Therapeutics, Inc. (AQST)
Growth Opportunities
Aquestive Therapeutics demonstrates potential growth through several strategic avenues:
Product Pipeline and Innovation
| Product | Development Stage | Potential Market Size |
|---|---|---|
| AQST-108 (CNS Treatment) | Phase 2 Clinical Trials | $1.2 billion estimated market potential |
| Libervant (Epilepsy Treatment) | FDA Approved | $750 million addressable market |
Market Expansion Strategies
- Expanding pharmaceutical portfolio in neurological disorders
- Targeting 3-5% market share in CNS treatment segment
- Exploring international market opportunities
Revenue Growth Projections
Financial forecasts indicate potential revenue growth:
| Year | Projected Revenue | Growth Rate |
|---|---|---|
| 2024 | $45.2 million | 12.5% |
| 2025 | $53.8 million | 18.9% |
Strategic Partnerships
- Collaboration with major pharmaceutical research institutions
- Potential licensing agreements for drug delivery technologies
- Strategic investments in research and development
Competitive Advantages
Key differentiators include:
- Proprietary drug delivery platform
- Advanced pharmaceutical formulation technologies
- Strong intellectual property portfolio with 12 active patents
Aquestive Therapeutics, Inc. (AQST) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.